Inflammation and clinical decline after adjuvant chemotherapy in older adults with breast cancer

Older breast cancer survivors are at increased risk of clinical decline after adjuvant chemotherapy. The Hurria Older Patients Prospective Study evaluated whether inflammatory markers assessed before adjuvant chemotherapy are associated with chemotherapy-induced clinical decline in a population of fit older adults with breast cancer. The study showed that high IL-6 and CRP prechemotherapy were associated with chemotherapy-induced decline in frailty status, independent of sociodemographic and clinical risk factors.